1.
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
by Bieniasz, Paul D
Nature, 2008-01-24, Vol.451 (7177), p.425-430
2.
Adaptation of HIV-1 to human leukocyte antigen class I
by KAWASHIMA, Yuka
Nature, 2009, Vol.458 (7238), p.641-645
3.
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
by Korber, Bette T
Nature medicine, 2007-01, Vol.13 (1), p.100-106
4.
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
by Gray, Glenda E, Prof
The Lancet infectious diseases, 2014, Vol.14 (5), p.388-396
5.
Architecture and secondary structure of an entire HIV-1 RNA genome
by Weeks, Kevin M
Nature (London), 2009-08-06, Vol.460 (7256), p.711-716
6.
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
by Nussenzweig, Michel C
Nature, 2009-04-02, Vol.458 (7238), p.636-640
7.
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment
by Clarke, David K
Vaccine, 2016, Vol.34 (51), p.6597-6609
8.
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients
by VAN GULCK, Ellen
AIDS (London), 2012, Vol.26 (4), p.F1-F12
9.
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
by Barouch, Dan H
Nature medicine, 2010-03, Vol.16 (3), p.319-323
10.
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
by Xu, Kai
Nature medicine, 2018-06, Vol.24 (6), p.857-867
11.
SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells
by Baldauf, Hanna-Mari
Nature medicine, 2012-11, Vol.18 (11), p.1682-1688
12.
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial
by Gray, Ronald H, Prof
The Lancet (British edition), 2007, Vol.369 (9562), p.657-666
13.
Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2...
by Rossetti, B
Clinical microbiology and infection, 2018-04, Vol.24 (4), p.422-427
14.
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial
by Hertz, T
Vaccine, 2016, Vol.34 (47), p.5792-5801
15.
Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Côte d’Ivoire
by Ayouba, Ahidjo
AIDS (London), 2013-09-24, Vol.27 (15), p.2488-2491
16.
Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag–pol–nef antigen
by Herath, S
Vaccine, 2015, Vol.33 (51), p.7283-7289
17.
Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines
by Xu, Rong
Vaccine, 2008, Vol.26 (37), p.4819-4829
18.
Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge
by Sholukh, Anton M
Vaccine, 2015, Vol.33 (17), p.2086-2095
19.
Immunogenicity of sequences around HIV-1 protease cleavage sites: Potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites
by Luo, Ma
Vaccine, 2013, Vol.31 (29), p.3000-3008
20.
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans
by Koff, Wayne C
Nature medicine, 2008-06, Vol.14 (6), p.617-621
